Case number IPR2017-02127
Pfizer, Inc. v. Genentech, Inc. > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Oct 6, 2017 | 1 | Petitioner's Power of Attorney Download | |
| Oct 6, 2017 | 2 | PETITION FOR INTER PARTES REVIEW '711 Download | |
| Oct 30, 2017 | 3 | Power of Attorney Download | |
| Oct 30, 2017 | 4 | Mandatory Notice Download | |
| Nov 6, 2017 | 5 | Notice of Accord Filing Date Download | |
| Dec 27, 2017 | 6 | Patent Owners' Updated Mandatory Notice Download | |
| Jan 31, 2018 | 7 | Petitioner's Updated Mandatory Notice Download | |
| Feb 6, 2018 | 8 | Patent Owner Preliminary Response Download | |
| Feb 6, 2018 | 9 | Patent Owner Exhibit List Download | |
| Apr 19, 2018 | 10 | Trial Instituted Document Download | |
| May 31, 2018 | 11 | Motion for Refund of Post-Institution Fee Download | |
| Jun 21, 2018 | 12 | Notice of Refund Download | |
| Oct 6, 2017 | 1001 | Ex. 1011 - White et al., U.S. Patent No. 8,206,711 Download | |
| Oct 6, 2017 | 1002 | Ex. 1002 - Declaration of Howard Ozer, M.D., Ph.D. Download | |
| Oct 6, 2017 | 1003 | Ex. 1003 - D.G. Maloney et al., "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," Blood, 84(8):2457-2466 (1994) Download | |
| Oct 6, 2017 | 1004 | Ex. 1004 - Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195 (1997) Download | |
| Oct 6, 2017 | 1005 | Ex. 1005 - Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," J. Clinical Oncology, 15(10):3266-3274 (1997) Download | |
| Oct 6, 2017 | 1006 | Ex. 1006 - Press Release, Genentech, Inc. "Genentech and IDEC Pharmaceuticals to Collaborate on Anti-CD20 Monoclonal Antibody for B-Cell Lymphomas," (March 16, 1995) Download | |
| Oct 6, 2017 | 1007 | Ex. 1007 - O'Brien et al., "Fludarabine (FAMP) and Cyclophosphamide (CTX) Therapy in Chronic Lymphocytic Leukemia (CLL)," Blood, 88(10 Supp. 1):480a (1996) Download | |
| Oct 6, 2017 | 1008 | Ex. 1008 - Thomas J. Kipps, "Chronic Lymphocytic Leukemia and Related Diseases," in Williams Hematology 5th Ed. (Beutler et al., eds.) 1017-1039 (1995) Download | |
| Oct 6, 2017 | 1009 | Ex. 1009 - Jensen et al., "Rapid Tumor Lysis in a Patient with B-cell Chronic Lymphocytic Leukemia and Lymphocytosis Treated with an Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)," Ann. Hematology, 77:89-91 (1998) Download | |
| Oct 6, 2017 | 1010 | Ex. 1010 - I. W. Flinn et al., "Fludarabine and Cyclophosphamide as First Therapy for Indolent Lymphoproliferative Disorders: Response Rates and Toxicity," Blood, 88(10):589a (1996) Download | |
| Oct 6, 2017 | 1011 | Ex. 1011 - Czuczman et al., "IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma," Blood, 86(10 Supp. 1):55a (1995) Download | |
| Oct 6, 2017 | 1012 | Ex. 1012 - McLaughlin et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," J. Clinical Oncology, 16(8):2825-2833 (1998) Download | |
| Oct 6, 2017 | 1013 | Ex. 1013 - Rituxan (rituximab) labeling (Nov. 1997) Download | |
| Oct 6, 2017 | 1014 | Ex. 1014 - Excerpts from Clinical Oncology, Abeloff et al., Eds. (1995) Download | |
| Oct 6, 2017 | 1015 | Ex. 1015 - Coiffier et al., "Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lymphoma: A multicenter Phase II Study," Blood, 92(6):1927-1932 (1998) Download | |
| Oct 6, 2017 | 1016 | Ex. 1016 - Grossbard et al., "Monoclonal Antibody-Based Therapies of Leukemia and Lymphoma," Blood, 80(4):863-878 (1992) Download | |
| Oct 6, 2017 | 1017 | Ex. 1017 - Caroline McNeil, "Non-Hodgkin's Lymphoma Trials In Elderly Look Beyond CHOP," J. Nat'l Cancer Inst., 90(4):266-267 (Feb. 18, 1998) Download | |
| Oct 6, 2017 | 1018 | Ex. 1018 - U.S. Application No. 09/436,347 (dated Nov. 9, 1999) Download | |
| Oct 6, 2017 | 1019 | Ex. 1019 - U.S. Application No. 09/436,347, Non-Final Office Action (dated Feb. 29, 2000) Download | |
| Oct 6, 2017 | 1020 | Ex. 1020 - U.S. Application No. 09/436,347, Amendment and Response to Rejection (dated Aug. 29, 2000) Download | |
| Oct 6, 2017 | 1021 | Ex. 1021 - U.S. Application No. 09/436,347, Request for Continued Examination (dated Aug. 7, 2006) Download | |
| Oct 6, 2017 | 1022 | Ex. 1022 - U.S. Application No. 09/436,437, Final Office Action (dated Feb. 19, 2009) Download | |
| Oct 6, 2017 | 1023 | Ex. 1023 - Second Declaration of David P. Schenkein, M.D. (May 5, 2009) Download | |
| Oct 6, 2017 | 1024 | Ex. 1024 - U.S. Application No. 09/436,437, Amendment and Response to Rejection (dated May 29, 2009) Download | |
| Oct 6, 2017 | 1025 | Ex. 1025 - U.S. Application No. 09/436,437, Supplemental Amendment and Remarks (dated Aug. 24, 2009) Download | |
| Oct 6, 2017 | 1026 | Ex. 1026 - U.S. Application No. 09/436,437, Notice of Allowance (dated Sept., 9, 2009) Download | |
| Oct 6, 2017 | 1027 | Ex. 1017 - U.S. Application No. 12/629,472, Amendment and Response to Rejection, (dated Apr. 24, 2012) Download | |
| Oct 6, 2017 | 1028 | Ex. 1028 - Celltrion, Inc. v. Biogen, Inc., Petition for Inter Partes Review, IPR2017-01229 (U.S. Patent No. 8,206,711), Paper 3 (Mar. 31, 2017) Download | |
| Oct 6, 2017 | 1029 | Ex. 1029 - Celltrion, Inc. v. Biogen, Inc., Patent Owner Preliminary Response, IPR2017-01229 (U.S. Patent No. 8,206,711), Paper 8 (July 24, 2017) Download | |
| Oct 6, 2017 | 1030 | Ex. 1030 - Pfizer, Inc. v. Biogen, Inc., Patent Owner Preliminary Response, IPR2017-01166, Paper 7 (Aug. 15, 2017) Download | |
| Oct 6, 2017 | 1031 | Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 2 Download | |
| Oct 6, 2017 | 1031 | Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 1 Download | |
| Oct 6, 2017 | 1031 | Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 2 Download | |
| Oct 6, 2017 | 1031 | Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 3 Download | |
| Oct 6, 2017 | 1031 | Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 2 Download | |
| Oct 6, 2017 | 1032 | Ex. 1032 - Demidem et al., "Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs," Cancer Biotherapy & Radiopharmaceuticals, 12(3):177-186 (1997) Download | |
| Oct 6, 2017 | 1033 | Ex. 1033 - First Declaration of David P. Schenkein, M.D. (April 14, 2008) Download | |
| Oct 6, 2017 | 1034 | Ex. 1034 - "Rituximab: Full Prescribing Information," (Wayback Machine) Download | |
| Feb 6, 2018 | 2001 | Ex 2001 Chronic Lymphocytic Leukemia Download | |
| Feb 6, 2018 | 2002 | Ex 2002 Definition of Leukemia Download | |
| Feb 6, 2018 | 2003 | Ex 2003 Almasri-Reduction Expression of CD20 Antigen Download | |
| Feb 6, 2018 | 2004 | Ex 2004 Cheson-Revised Guidelines for Chronic Lymphocytic Leukemia Download | |
| Feb 6, 2018 | 2005 | Ex 2005 Kipps-Chronic lymphocytic leukemia and related diseases Download | |
| Feb 6, 2018 | 2006 | Ex 2006 Amendment & Reply Download | |
| Feb 6, 2018 | 2007 | Ex 2007 Request for Continued Examination Download | |
| Feb 6, 2018 | 2008 | Ex 2008 09/436,347 File History-Part 2 Download | |
| Feb 6, 2018 | 2008 | Ex 2008 09/436,347 File History-Part 2 Download | |
| Feb 6, 2018 | 2008 | Ex 2008 09/436,347 File History-Part 1 Download | |
| Feb 6, 2018 | 2009 | Ex 2009 Corrected Substitute Specification for App. No. 09/436,347 Download | |
| Feb 6, 2018 | 2010 | Ex 2010 Clinical Development Success Rates 2006-2015 Download |
